Opinion

Video

Recent Data on Anti-TROP2 ADCs for Patients With Advanced or Recurrent Endometrial Cancer

Author(s):

Bradley Monk, MD,Dana M. Chase, MD, FACOG

The panel highlights recent data on antibody drug conjugates targeting TROP2 in patients with advanced or recurrent endometrial cancer and the need for dose optimization.

Related Videos
Kathleen N. Moore, MD, MS
5 KOLs are featured in this series.
Related Content
Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Stephanie Gaillard, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
December 10th 2024

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

FDA
December 5th 2024

FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer

Cadonilimab Plus Chemotherapy in Cervical Cancer | Image Credit: © Dr_Microbe - stock.adobe.com
December 3rd 2024

Cadonilimab Plus Chemotherapy Provides Frontline Survival Benefit in Metastatic Cervical Cancer